Andere talen Mineralys Therapeutics, Inc.

Aandelen

MLYS

US6031701013

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 10-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
13,52 ^USD	-5,26%		+4,40%	+57,21%

09/05	Transcript : Mineralys Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
09/05	Mineralys Therapeutics, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Mineralys Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	09/05
Mineralys Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Mineralys Therapeutics to Participate in the Bank of America Securities Health Care Conference	06/05
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024	02/05
Mineralys Therapeutics, Inc. Announces Alexander Asam Informs That His Decision Not to Stand for Re-Election to the Board	04/04
Mineralys Therapeutics Files Mixed-Securities Shelf Registration	21/03
Mineralys Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Mineralys Therapeutics : Corporate Overview March 2024	21/03
Mineralys Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	21/03
Mineralys Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
North American Morning Briefing : Investors -2-	21/03
Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on Thursday, March 21, 2024	13/03
Sector Update: Health Care Stocks Ease in Late Afternoon	08/02
Sector Update: Health Care	08/02
Mineralys Therapeutics Secures $120 Million Financing Through Private Placement; Shares Rise	08/02
Mineralys Therapeutics Announces $120 Million Private Placement Financing	08/02
Mineralys Therapeutics, Inc. announced that it expects to receive $119.999925 million in funding from TCG Crossover Management, LLC, OrbiMed Advisors LLC, RA Capital Management, L.P., Samsara BioCapital LLC, VR Adviser, LLC	07/02
Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference	29/01
Mineralys Therapeutics Names Minji Kim as Chief Business Officer	04/01
Mineralys Therapeutics Appoints Minji Kim, Ph.D. as Chief Business Officer	04/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Mineralys Therapeutics, Inc.

Aandelen

MLYS

US6031701013

Andere talen

Filters